Virbac (VIRP) Resumen de Acciones
Virbac SA fabrica y vende una gama de productos y servicios para animales de compañía y de granja en Europa, Norteamérica, Latinoamérica, Asia Oriental, India, África, Oriente Medio y el Pacífico. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en VIRP a partir de nuestros controles de riesgos.
VIRP Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.3% infravalorado descuento intrínseco
5022.2%Revenue growth p.a.
3.7k
23
2
54
Competidores de Virbac SA
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €371.50 |
| Máximo en las últimas 52 semanas | €389.50 |
| Mínimo de 52 semanas | €296.00 |
| Beta | 0.81 |
| Cambio en 1 mes | 5.84% |
| Variación en 3 meses | 5.69% |
| Cambio de 1 año | 18.12% |
| Variación en 3 años | 25.93% |
| Variación en 5 años | 39.14% |
| Variación desde la OPV | 2,923.27% |
Noticias y actualizaciones recientes
VIRP: Human Animal Bond Partnership Will Support 2026 Outlook Repricing
Analysts have made a small adjustment to their Virbac price target to reflect marginal tweaks in fair value, growth and margin assumptions, trimming it by about €0.50 to €412.33. What's in the News Virbac entered a new partnership with the Human Animal Bond Research Institute to support efforts that strengthen the human animal bond and its impact on companion animal and human health, focusing on science, education and collaboration (Key Developments).VIRP: Stable Assumptions And 2026 Guidance Will Support Bullish Repricing
Analysts have maintained their Virbac price target at €412.82, indicating unchanged views on fair value, discount rate, growth assumptions, and margin expectations for the company. What's in the News Virbac entered a partnership with the Human Animal Bond Research Institute (HABRI) to support efforts that strengthen the human animal bond and its impact on companion animal and human health, with a focus on science, education and collaboration (Key Developments).VIRP: Stable Inputs And 2026 Guidance Will Support Bullish Repricing
Analysts have kept Virbac's fair value estimate steady at €412.82 per share, with only small technical adjustments to inputs such as the discount rate and assumed future P/E informing this unchanged price target. What's in the News Virbac issued earnings guidance for 2026, including the impact of the Thyronorm acquisition, with revenue growth expected to be between 5.5% and 7.5% at constant rates and scope (Key Developments).Recent updates
VIRP: Human Animal Bond Partnership Will Support 2026 Outlook Repricing
Analysts have made a small adjustment to their Virbac price target to reflect marginal tweaks in fair value, growth and margin assumptions, trimming it by about €0.50 to €412.33. What's in the News Virbac entered a new partnership with the Human Animal Bond Research Institute to support efforts that strengthen the human animal bond and its impact on companion animal and human health, focusing on science, education and collaboration (Key Developments).VIRP: Stable Assumptions And 2026 Guidance Will Support Bullish Repricing
Analysts have maintained their Virbac price target at €412.82, indicating unchanged views on fair value, discount rate, growth assumptions, and margin expectations for the company. What's in the News Virbac entered a partnership with the Human Animal Bond Research Institute (HABRI) to support efforts that strengthen the human animal bond and its impact on companion animal and human health, with a focus on science, education and collaboration (Key Developments).VIRP: Stable Inputs And 2026 Guidance Will Support Bullish Repricing
Analysts have kept Virbac's fair value estimate steady at €412.82 per share, with only small technical adjustments to inputs such as the discount rate and assumed future P/E informing this unchanged price target. What's in the News Virbac issued earnings guidance for 2026, including the impact of the Thyronorm acquisition, with revenue growth expected to be between 5.5% and 7.5% at constant rates and scope (Key Developments).VIRP: Broad Regional Execution And 2026 Outlook Will Support Bullish Repricing
Narrative Update The analyst price target for Virbac has been raised from €390 to €415, with analysts citing accelerated growth across all regions as the key driver of this change. Analyst Commentary Analysts lifting their price target on Virbac to €415 from €390 are focusing on how the company is executing its growth plans across regions and what that could mean for valuation and risk.VIRP: Broad Regional Acceleration Will Support Upgraded Buy Rating Into 2025
Narrative Update on Virbac Analysts have increased their price target on Virbac to €415 from €390, citing what they describe as accelerated growth across all regions as the key driver for their updated view. Analyst Commentary Recent research points to a more constructive stance on Virbac, with analysts raising their price target to €415 from €390 as they reassess the company’s growth profile.VIRP: Broad Regional Acceleration Will Sustain Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac from EUR 390 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to a higher price target as a reflection of stronger than expected execution in scaling operations across all regions.VIRP: Broad Regional Momentum Will Support Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac by EUR 25 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Following the recent upgrade, research coverage has focused on the sustainability of Virbac’s growth acceleration and its implications for valuation.VIRP: Accelerated Regional Momentum Will Sustain an Upgraded Bullish Outlook for 2025
Analysts have raised Virbac's price target from €390 to €415, citing accelerated growth across all regions as the key driver for their more positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts cite a clear acceleration in Virbac's growth across all geographic regions, which supports a more positive outlook for the company.VIRP: Accelerated Regional Expansion Will Drive Upgraded Earnings Outlook Next Year
Narrative Update on Virbac Analysts have raised Virbac's price target from €398 to €403, citing accelerated growth across all regions as the primary driver for this upward revision. Analyst Commentary The most recent research notes reflect increased optimism around Virbac's trajectory, with upward revisions to both rating and price targets.Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?
Oct 05
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Sep 17There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price
Aug 30Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?
Jun 23Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
May 18Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly
Apr 30
Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals
Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability.Earnings Not Telling The Story For Virbac SA (EPA:VIRP)
Jan 24An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Oct 06Virbac SA Just Beat Revenue Estimates By 6.0%
Sep 18Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
Aug 31Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Jun 15Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Jun 10Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
May 21Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Mar 22Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Jan 18Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Dec 27Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Oct 19Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Sep 26Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
Sep 05A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Jun 20Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
May 31Is Virbac (EPA:VIRP) Using Too Much Debt?
Apr 09Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Feb 28Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 25Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Oct 14An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Aug 07These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
Jun 26Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
May 01We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
Mar 26Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
Jan 26Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Dec 28A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Oct 27Is Virbac (EPA:VIRP) Using Too Much Debt?
Oct 12Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today
Sep 26Rentabilidad de los accionistas
| VIRP | FR Pharmaceuticals | Mercado FR | |
|---|---|---|---|
| 7D | -1.8% | -0.05% | -0.6% |
| 1Y | 18.1% | -12.4% | -0.2% |
Rentabilidad vs. Industria: VIRP superó a la industria French Pharmaceuticals, que obtuvo un rendimiento del -12.4% el año pasado.
Rentabilidad vs. Mercado: VIRP superó al mercado French, que obtuvo un rendimiento del -0.2% el año pasado.
Volatilidad de los precios
| VIRP volatility | |
|---|---|
| VIRP Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.3% |
| 10% least volatile stocks in FR Market | 2.9% |
Precio estable de las acciones: VIRP no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado French.
Volatilidad a lo largo del tiempo: La volatilidad semanal de VIRP (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1968 | 6,365 | Paul Martingell | corporate.virbac.com |
Virbac SA fabrica y vende una gama de productos y servicios para animales de compañía y de granja en Europa, Norteamérica, Latinoamérica, Asia Oriental, India, África, Oriente Medio y el Pacífico. La empresa ofrece una gama de vacunas, antibióticos, parasiticidas y antiinflamatorios, así como productos dermatológicos, dentales, especializados, de diagnóstico, nutrición, alimentos para animales de compañía y farmacéuticos. Atiende a veterinarios, ganaderos y propietarios de animales de compañía.
Resumen de fundamentos de Virbac SA
| Estadísticas fundamentales de VIRP | |
|---|---|
| Capitalización bursátil | €3.11b |
| Beneficios(TTM) | €150.89m |
| Ingresos (TTM) | €1.46b |
20.6x
Ratio precio-beneficio (PE)2.1x
Ratio precio-ventas (PS)¿Está VIRP sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de VIRP | |
|---|---|
| Ingresos | €1.46b |
| Coste de los ingresos | €487.96m |
| Beneficio bruto | €976.71m |
| Otros gastos | €825.83m |
| Beneficios | €150.89m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
Sep 17, 2026
| Beneficios por acción (BPA) | 18.01 |
| Margen bruto | 66.68% |
| Margen de beneficio neto | 10.30% |
| Ratio deuda/patrimonio | 22.3% |
¿Cómo se ha desempeñado VIRP a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.4%
Rentabilidad actual por dividendo8%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/02 09:10 |
| Precio de las acciones al final del día | 2026/04/30 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Virbac SA está cubierta por 12 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Delphine Le Louet | Bernstein |
| Laurent Gelebart | BNP Paribas |
| Arnaud Cadart | CIC Market Solutions (ESN) |